Le Lézard
Classified in: Health, Science and technology
Subjects: SVY, MAT

Biotechnology Company Purissima Releases Study Findings Related to the Potential Applications and Usage of Cannabichromene (CBC)


Study's Results Reveal CBC's Robust Therapeutic Properties to Help Contribute to Skin Health

SAN FRANCISCO, Sept. 8, 2022 /PRNewswire/ -- Purissima, a leading biotechnology health and wellness company, announced the completion of two separate ingredient testing programs with two leading contract research organizations. Testing included biological tests on human skin explants to reveal the effectiveness of Purissima's produced compounds Cannabichromene (CBC) and Cannabichromenic acid (CBCA). While scientific studies and literature do currently exist surrounding the generalized efficacy of CBC on the human body, Purissima conducted these independent surveys to specifically validate and confirm CBC's therapeutic potential to improve a variety of topical skin concerns. To date, given the lack of commercial availability of CBCA (aside from being naturally produced by Purissima), there is limited published scientific studies and literature.

The collected test data indicated CBC did have a significant and positive impact on helping soothe stressed and irritated skin. The physical manifestation of this marked improvement included a reduction in the appearance of skin redness, and decrease in the appearance of skin inflammation.          

"Our testing helped us further quantify and substantiate the effectiveness of our CBC compound," said Karen Raghavan, VP of Brand Development at Purissima. "It is our mission to help improve the quality of life for millions of people on the planet, and the findings further elucidate the efforts and potential biotechnology has to radically innovate the global health, wellness, and pharmaceutical sectors at an unprecedented scale and speed."

Other nuanced survey findings signaling CBC's beneficial properties in topical ingredient usage included:

Purissima has also conducted another independent study with a leading contract research organization resulting in data that confirms broad and potent antibacterial and antifungal properties that would imply compelling skin care applications.

This survey was conducted following Purissima's July 2022 announcement of their exclusive production and manufacturing contract with Open Book Extracts. Purissima has proven scalable production of Cannabichromene (CBC) via microalgae fermentation and will be launching CBC to market at commercial scale in September 2022 with Open Book Extracts.

ABOUT PURISSIMA

Purissima Inc. is revolutionizing the way companies source and use plant-based ingredients, through the development and production of commercially viable, microalgae biotechnology. Purissima's mission is to provide the world access to high-quality, pure, safe, and sustainable ingredients for products that improve the quality of life for millions. Purissima has sustainably and effectively biosynthesized 70+ natural ingredients, including those rare or hard to access, at a fraction of the cost and without adverse environmental, varietal or supply chain impact. The brand's patented and proprietary biotechnology advances critical plant-derived health + wellness solutions while preserving Earth's biodiversity and natural resources.

SOURCE Purissima


These press releases may also interest you

at 05:09
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...

at 02:30
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...



News published on and distributed by: